Membrane Proteome Profiling of Peripheral Immune Cells in Non-Small Cell Lung Cancer Patients Treated with First Line Combination Chemotherapy

Four lung adenocarcinoma patients with progression free survival (PFS) ranged from 2.13 to 14.5 months were recruited in the study. Paired PBMCs were collected before and after first regimen of PEM/CIS treatment for individualized analysis of membrane proteome profiles. The membrane protein fractions were purified from PBMCs, subjected to gel-assisted digestion, labeled with iTRAQ reagents, fractionated by high-pH reversed phase StageTip, and analyzed in duplicate by LC-MS/MS. Protein identification and quantitation was obtained by using Mascot with 1% false discovery rate and Multi-Q.